Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.

Nelson CP, Lai FY, Nath M, Ye S, Webb TR, Schunkert H, Samani NJ.

Circ Genom Precis Med. 2019 Jan;12(1):e002196. doi: 10.1161/CIRCGEN.118.002196.

https://www.ncbi.nlm.nih.gov/pubmed/30645167